Macrophages are key components of the innate immune system. Ubiquitous throughout the body, macrophages defend against harmful microbes, remove apoptotic cells, and promote tissue repair after injury 1 . Upon sensing microbial products, activated macrophages release inflammatory cytokines and chemokines that recruit additional inflammatory cells and cause both local and systemic inflammation. A robust inflammatory response by macrophages can also lead to significant tissue injury 2, 3 . Dysregulation of macrophage activation and inflammation contributes to multiple diseases, including atherosclerosis, diabetes, and cancer [4] [5] [6] . When playing a trophic role, macrophages can drive tissue fibrosis and tumor growth and metastases [7] [8] [9] . Therefore understanding macrophages and their diverse functions could generate new strategies for combatting human disease.
Tissue macrophages are heterogeneous. For example, the lung contains alveolar macrophages, interstitial macrophages, patrolling monocytes, and airway dendritic cells that originate from macrophage/monocyte precursors. The macrophage populations in various tissues appear to arise from unique progenitors during different stages of development. Macrophages populate the embryo and fetus in three successive waves 10, 11 . In mice, Csf1r+ erythromyeloid progenitors within the yolk sac endothelium give rise to F4/80 HI macrophages throughout the embryo beginning at embryonic day 7 (E7). At E9, Myb+ precursors from the yolk sac establish a second site of hematopoiesis within the embryonic liver. From the liver, a second wave of CD11b HI macrophages appear around E12, differentiate into tissue-specific macrophages, and can persist into adulthood. In the lung, these CD11b HI cells differentiate into alveolar macrophages through GM-CSF and TGFβ signaling 12, 13 . A third wave occurs after definitive hematopoiesis moves to the bone marrow, partially replacing embryonic yolk sac derived cells with bone marrow derived macrophages via the circulation 14 . While recent publications have shed new light on the origins of macrophage populations, less is known about the functional differences each population plays in immunity.
The fetal and newborn periods present unique immunological challenges. The maternal-fetal immune systems must maintain a tolerant state to prevent attack of the developing fetus by the maternal immune system and also fetal response against maternal antigens 15 . Persistence of tolerance after birth may allow colonization of the newborn with beneficial microbiota and minimize overzealous responses to ingested food antigens 16, 17 In infants born before 30 wk gestation, macrophage-mediated lung inflammation leads to bronchopulmonary dysplasia [19] [20] [21] [22] [23] . A chronic developmental lung disease, bronchopulmonary dysplasia is the most common serious complication of prematurity. In response to mechanical ventilation, infection, and high oxygen exposure, activated lung macrophages stimulate inflammation that prevents normal postnatal airway branching and alveolar formation 24, 25 . Both patient and animal studies have implicated macrophage-derived IL-1β as a key cytokine that drives inflammation, injury, and abnormal structural development 22, 26, 27 . IL-1β release requires both NF-κB mediated Il1b transcriptional activation and processing of the pro-IL-1β peptide by inflammasome associated caspase activity. While multiple inflammasome versions exist, the NLRP3-ASC-CASP1 complex is required for lung inflammation and injury in mouse models 22, 27 . Inflammasome function and IL-1β release in the lung is developmentally regulated. Inflammatory stimuli and macrophage activation only impact lung development during later stages of embryonic development 22, 28 . The molecular and cellular mechanisms producing this developmental window of susceptibility however are not clear. Here we use flow sorting techniques to isolate macrophage populations from embryonic mice and show that inflammasome function and IL-1β release is specifically restricted to the population of macrophages derived from the fetal liver. By identifying the cell populations that produce tissue inflammation and injury within the developing embryo, our findings will lead to more targeting therapeutic approaches for combatting neonatal inflammatory diseases.
Material and Methods
Approvals. Animal experiments were approved by the Institutional Animal Care and Use Committee at University of California, San Diego. All experimental methods were carried out in accordance with the rules, regulations, and guidelines established by the University of California, San Diego Institutional Animal Care and Use Program.
Mouse strains. C57BL/6 mice were obtained from Harlan Laboratories. LysM-Cre-NLRP3 L351P mice were developed and described previously 29 . The morning of plug identification was defined as embryonic day 0 (E0). Embryos were harvested at E13, E15 or E18. Dissections were performed in cold PBS.
Fetal macrophage isolation.
Fetal organs (lung, liver, brain) and yolk sacs were collected in cold PBS containing EDTA (2 mM) and fetal bovine serum (FBS-2%). Tissues were homogenized and enzymatically digested with collagenase IV (2 mg/ml) for 15 min. red blood cells were lysed with ACK buffer (Life Technologies) for 5 min. Cells suspensions were passed through a 70-μm cell strainer.
Flow cytometry and cell sorting. Isolated single cell suspensions were first incubated with FC block and Zombie NIR or Aqua live/dead stain (Biolegend) for 15 min in PBS. Conjugated antibodies in staining buffer (2% FBS + 2%EDTA in PBS) were then added for an additional 30 min incubation. For intracellular staining, cells were fixed using IC fixation and permeabilization buffers according to manufacturer's recommendation (eBioscience). The following antibodies were used for flow sorting: CD45-FITC, CD64-Percp-Cy5.5, F4/80-PE and CD11b-V450. For flow cytometry analysis and intracellular staining, the following additional antibodies were used: CD68-AF647, pro-IL1β-PE-Cy7, TNF-APC-Cy7, NLRP3-APC and CD45-V500.
Flow cytometry measurements were performed on a BD Canto II (BD Biosciences). Sorting was performed on a FACS Aria cell sorter. The following gating strategy was used: doublets were excluded based on forward scatter-A against forward scatter-W, followed by side scatter-A against side scatter-W. Live cells were selected using Zombie LIVE/DEAD stain. CD45+ and CD64+ cells were then selected and further separated based on F4/80 and CD11b expression. Yolk sac derived macrophages express higher F4/80 and lower CD11b levels while fetal monocytes express lower F4/80 and higher CD11b levels. Sorted cells were cultured in suspension in DMEM with 10% FBS with or without gel purified lipopolysaccharide (LPS) from 055:B5 E. coli (Sigma L2637). This low-protein preparation of LPS does not appear to activate other Toll-Like Receptors 30, 31 .
RNA isolation and real-time PCR measurement. Cells were homogenized in TRIzol reagent (Invitrogen) and RNA was isolated using Direct-Zol RNA miniprep kit (Zymo Research). After RNA isolation, cDNA was synthesized using first-strand cDNA synthesis kit (Invitrogen). Real-time PCR was performed in CFX96 thermocycler (Bio-Rad) using unlabeled oligonucleotides (IDT) and SYBR Green (Bio-Rad). Gene expression data was presented using the 2 −ΔCt method, using TBP as reference gene. The sequences of qPCR primers used are as followed: Tbp: 5′-ACA TCT CAG CAA CCC ACA CA and 5′-CTG CTG TGG CAG GAG TGA TA; Il1b: 5′-GAC CTG TTC TTT GAA GTT GAC GGA CC and 5′-CAA TGA GTG ATA CTG CCT GCC TGA AG; Il6: 5′-ACA ACC ACG GCC TTC CCT AC and 5′-ACA ATC AGA ATT GCC ATT GCA C; Nlrp3: 5′-GAC CAT CGG CCG GAC TAA AA and 5′-CTT GCA CAC TGG TGG GTT TG; Pf4: 5′-CCG AAG AAA GCG ATG GAG ATC T and 5′-CCA GGC AAA TTT TCC TCC CA; Igf1: 5′-GTG AGC CAA AGA CAC ACC CA and 5′-.ACC TCT GAT TTT CCG AGT TGC.
ELISA.
For measurements of IL-1β and IL-6 in culture supernatants, we used the Ready-Set-GO ELISAs kits according to manufacturer's protocol (eBioscience).
Monocyte depletion. For Ly6C+ monocyte depletion, pregnant mice received 3 intraperitoneal injections of anti-Ly6G/Ly6C (clone RB6-8C5, Bioxcell) antibody or the isotype control (rat IgG2b anti-KLH, clone LTF-2, Bioxcell), starting at E12. For the first injection, mice received 1 mg of antibodies, then 2 mg for the second and third injections. Embryos were collected at E15. Processing was performed in the UCSD Stem Cell Genomics Core at the Sanford Consortium for Regenerative Medicine. Data analysis was performed using nSolver 4.0 according to NanoString guidelines. Raw mRNA counts were normalized to account for hybridization efficiency, background noise, and sample content. Genes with mean counts less than 20 were excluded, and differential expression of remaining genes was calculated and represented on a volcano plot, using a nonparametric t-test and correction for multiple testing using the BH false discovery rate (FDR). Mouse single site analysis of conserved transcription factor (TF) binding sites in the list of differentially expressed genes was performed using oPOSSUM 3.0 (http://opossum.cisreg.ca/oPOSSUM3/), using JASPAR core profile and the oPOSSUM gene database as background.
Results

CD11b
HI fetal lung macrophages are the primary sources of IL-1β and IL-6. Fetal lung inflammation following macrophage activation increases during the later stages of development. Here we tested if this temporal change was due to inflammatory differentiation of resident tissue macrophages or appearance of new pro-inflammatory cells later in development. Using a flow sorting approach ( Fig. 1a) , we first demonstrated the timing of when different macrophage populations appeared in the developing mouse lung (Fig. 1b) (Fig. 1c) .
To test if yolk sac F4/80 HI and fetal liver derived CD11b HI lung macrophage populations had distinct functional properties, we sorted both macrophage populations from E15 lungs and stimulated them with the TLR4 agonist LPS (gel purified from E. coli, O55:B5). Importantly, freshly sorted cells were kept in suspension and treated with LPS immediately upon sorting to reduce potential phenotypic changes with cell culture. LPS increased both Il1b and Il6 mRNA expression and IL-1β and IL-6 protein release in CD11b HI macrophages (Fig. 1d) . F4/80 HI macrophages expressed very low cytokine mRNA levels and did not release detectable amounts of cytokine peptides either under control conditions or upon LPS treatment. We also measured intracellular IL-1β and TNF within LPS-treated E15 lung cell suspensions using FACS (Fig. 1e,f HI macrophages appearing in the fetal lung after E13 were therefore more pro-inflammatory after LPS stimulation and with higher cytokine expression and release.
LPS-induced cytokine release is also restricted to CD11b
HI macrophages in the fetal liver. To test if the functional differences between macrophage populations were tissue specific, we next isolated F4/80 HI and CD11b HI macrophages from E15 fetal liver and measured their LPS response (Fig. 2a) . Similar to lung macrophages, LPS stimulated cytokine expression and release in CD11b HI fetal liver macrophages but not in F4/80 HI macrophages (Fig. 2b,c) . Of note, cytokine expression was lower in E15 liver CD11b HI macrophages compared to CD11b HI cells isolated from E15 lung as measured in Fig. 1 . We next compared the dose response and time course of LPS activation between the two fetal macrophage populations. As shown in Fig. 2d, F4/80 HI macrophages failed to respond at all LPS concentrations tested. We also did not detect increased Il1b or Il6 mRNA in LPS-treated F4/80 HI macrophages over a 4 h time course. These data further confirm the proinflammatory phenotype in fetal CD11b HI macrophages and the resistance to LPS in fetal F4/80 HI macrophages. To test if the differential response to LPS was present earlier in development, we isolated macrophage populations from yolk sac, liver, and lung at E13 (Fig. 3a) . LPS did not induce cytokine expression in F4/80 HI E13 macrophages from any of the tissue sources tested. At E13, only the liver contained CD11b HI macrophages, and these cells did express IL-1β and IL-6 following LPS treatment. Interestingly, F4/80 HI cells from the E13 liver appeared to express higher basal levels of Il1b and Il6 mRNA compared to macrophages from yolk sac and lung, but cytokine expression did not change with LPS. E13 liver F4/80 HI macrophages also did not release cytokine peptides into the media after LPS treatment. While both F4/80 HI and CD11b HI macrophages populate most tissues within the developing embryo, the brain contains primarily F4/80 HI yolk sac macrophages. LPS treatment of F4/80 HI macrophages from E15 brain did not induce IL-1β expression or release (Fig. 3b) HI macrophages in mediating inflammation, we injected treatment (+/− s.e.m.; *P < 0.05, **P < 0.01, ***P www.nature.com/scientificreports www.nature.com/scientificreports/ pregnant dams with monoclonal anti-Gr-1 IgG to immunodeplete CD11b HI cells from developing embryos 32, 33 . Figure 4 shows that anti-Gr-1 injection reduced the number of Ly6C+/CD11b HI macrophages in the fetal liver at E15. When the total liver cell suspension was treated with LPS, Gr-1 depleted samples had reduced levels of IL-1β and IL-6 release equivalent with the level of depletion (Fig. 4a,b) . These data supported CD11b HI macrophages as a major population of cells in the fetal liver releasing IL-1β and IL-6 following LPS treatment. While anti-Gr-1 IgG immunodepleted Ly6C+ cells from the E15 lung, the number of CD11b HI macrophages was unchanged (Fig. 4c,d ). LPS stimulated IL-1β and IL-6 release was unaffected by anti-Gr-1 depletion in E15 lung samples, consistent with our hypothesis that CD11b HI macrophages were the main cellular source of IL-1β. HI macrophages from the lung did express higher levels of TLR4 compared to F4/80 HI macrophages (Fig. 5a,c) . However E15 liver macrophage populations expressed similar TLR4 levels (Fig. 5b,c) . Potential differences in TLR4 expression therefore did not appear to explain why F4/80 HI macrophages failed HI /Ly6C+ macrophages in the E15 fetal liver (a) with a corresponding reduction in IL-1β and IL-6 release following treatment of the total fetal liver cell suspension with LPS (*P < 0.05, n = 3; **P < 0.01, n = 4, ***P < 0.001, n = 4). Anti-Gr-1 injections did not reduce CD11b HI /Ly6C+ macrophages from fetal lungs or reduce IL-1β or IL-6 production following LPS treatment.
Tlr4 and Nlrp3 inflammasome expression in
www.nature.com/scientificreports www.nature.com/scientificreports/ to express inflammatory cytokines after LPS treatment. NLRP3 expression in the developing lung is restricted to macrophages and increases during the later stages of lung development. CD11b
HI macrophages from E15 lung expressed higher Nlrp3 compared to F4/80 HI macrophages (Fig. 6a) .
LPS increased Nlrp3 expression in CD11b
HI cells with minimal effect on F4/80 HI macrophages. Similar results were seen by immunostaining macrophages with antibodies against NLRP3 and the inflammasome linker protein ASC (Fig. 6b) . Expression and co-localization were more prevalent in CD11b HI cells. LPS treatment increased co-localization in both macrophage populations, with much higher ASC-NLRP3 co-localized signal in CD11b HI macrophages (Fig. 6c) . We next tested if constitutively active NLRP3 was sufficient to drive cytokine release in both CD11b
HI and F4/80 HI macrophages. We isolated E15 liver macrophages from Nlrp3 L351P mice expressing a gain of function mutation within the Nlrp3 gene. At E15, neither macrophage population released significant IL-1β under control conditions (Fig. 6d,e) . LPS treatment however stimulated both IL-1β and IL-6 release only in CD11b HI macrophages. F4/80 HI macrophages from E15 Nlrp3 L351P mice failed to express high levels of NLRP3 by confocal immunofluorescence, even after LPS treatment (Fig. 6f) . Nlrp3 L351P CD11b HI macrophages expressed both NLRP3 and ASC, with expression and colocalization increased after LPS treatment. Consistent with our data in wild type macrophages, these results show that fetal CD11b HI macrophages express NLRP3 inflammasome components and have the capacity to express and release IL-1β upon TLR4 stimulation. F4/80 HI macrophages however failed to express NLRP3, preventing their ability to release IL-1β. Coupled with the lack of both Il1b and Il6 mRNA in F4/80 HI macrophages, these data suggest that F4/80 HI macrophages lack an innate immune transcriptional response as well as the machinery necessary for generating pro-inflammatory activation.
Differential myeloid gene expression in LPS-treated fetal macrophages. The above experiments
focused on Il1b, Il6, and Nlrp3 in initially assessing the LPS-induced inflammatory response in F4/80 HI and CD11b HI fetal macrophages. To measure expression of additional genes, we used Nanostring nCounter gene expression profiling of 734 myeloid genes in LPS treated F4/80 HI and CD11b HI macrophages from E15 mouse lung (Fig. 7a) . A total of 89 genes were differentially expressed between the 2 macrophage populations (log 2 fold change >1; adjusted P < 0.05). CD11b
HI cells expressed higher levels of Il1a, Il1b, Ccl9, and Cxcl3, while F4/80 HI cells had higher expression of Pf4 (also known as Cxcl4), Igf1, and the complement genes C1qa, C1qb and C1qc (Fig. 7a) . Real time PCR confirmed higher C1qa and Pf4 expression in F4/80 HI macrophages and LPS did not increase expression of either gene (Fig. 7b) . To identify the molecular mechanisms of differential gene expression in the two macrophage populations, we examined TF binding sites enriched in LPS-induced genes in CD11b HI macrophages compared to F4/80 HI macrophages using Opossum 3.0 (Fig. 7c) . Overexpressed genes in CD11b HI macrophages were notably enriched in NF-κB binding sites, while the F4/80 HI macrophage gene signature contained motifs predicted to bind SRF, IRF1, and IRF2. In addition, RUNX1 predicted sites in F4/80 HI samples were consistent with data showing Runx1 expression is restricted to yolk sac derived macrophages 34 . In summary, our data suggest fetal macrophage populations have inherent differences in the transcriptional response machinery following exposure to LPS. HI lung macrophages, the relative expression of TLR4 in liver macrophage populations was similar (+/− s.e.m.; ***P < 0.001 compared to IgG isotype control, n = 4-6).
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Discussion
Fetal lung inflammation is developmentally regulated, with macrophage activation and cytokine release impacting airway morphogenesis only during the later stages of in utero development 22 . Here we show that developmental regulation of lung inflammation is due to the programmed accumulation of pro-inflammatory macrophages in the lung after E15. While we and others have shown macrophages do populate the lung from the initial days of embryonic development 12, 23, 35 , these early yolk sac derived macrophages appear resistant to pro-inflammatory TLR mediated activation. Our data here clearly demonstrate the functional differences between F4/80 HI yolk sac derived macrophages and CD11b HI fetal liver derived macrophages. CD11b HI macrophages express higher levels of inflammasome components and release IL-1β and IL-6 upon LPS treatment, while F4/80 HI macrophages fail to release these inflammatory mediators that play important roles in injury and disease.
Macrophage populations may share common functional properties in the moments following their differentiation from myeloid progenitors during fetal hematopoiesis. Upon trafficking to the circulation and into various tissues, the local microenvironment then shapes macrophage biology and promotes specialized, tissue specific functions 11, 36 . While the adult lung contains multiple immune cell populations including dendritic cells and lymphocytes, many of these cells appear after birth 37, 38 . However we still have not determined the relative heterogeneity within the various fetal macrophage populations studied here. At E15 when fetal liver derived CD11b HI macrophages are first trafficking to various tissues, cells isolated from the fetal lung had a slightly higher expression of inflammatory cytokines compared to cells still residing within the liver. The high levels of GM-CSF present in the lung could mediate these differences 39 . F4/80 HI cells from the yolk sac, liver, and lung remained resistant to LPS stimulation. The strikingly different situation identified for F4/80 HI cells is the developing fetal brain. Macrophages in the fetal brain are primarily F4/80 HI cells from the yolk sac, and these cells eventually differentiate into microglia 34, 40 . Not only do brain microglia have inflammatory potential, they also play a key role in forming mature synapses [41] [42] [43] . Interestingly, F4/80 HI macrophages from the E15 fetal brain did respond to www.nature.com/scientificreports www.nature.com/scientificreports/ LPS by increasing TNF expression. However they appeared to lack functional NLRP3 inflammasome expression and therefore failed to release IL-1β. Identifying the factors within the brain that give F4/80 HI cells their unique functional properties could provide important insight into both macrophage biology and neuroinflammatory disease processes.
The functional differences between fetal macrophage populations suggest unique molecular regulatory mechanisms. While both macrophage populations expressed similar levels of the LPS receptor TLR4, F4/80 HI macrophages did not express the same levels of NF-κB dependent genes after LPS treatment. Therefore F4/80 HI macrophages could have reduced expression of proteins required for the TLR-IKK-NF-κB or MAPK signaling pathways. Differential transcription factor expression or epigenetic chromatin modifications between CD11b HI and F4/80 HI macrophages could also explain why LPS generated unique responses in each cell population. Our informatics analysis clearly identified NF-κB promoter sites activated in CD11b HI macrophages that were apparently not accessible in F4/80 HI cells. Ongoing experiments are exploring the potential upstream mechanisms responsible for these differences. HI macrophages? F4/80 HI cells migrate throughout the entire embryo very early in development. The ubiquitous locations and lack of TLR-mediated inflammatory function suggest they play a role in tissue morphogenesis or homeostasis. Macrophages remove dying and apoptotic cells from both developing and mature tissues 44 . Multiple receptors on phagocytic cells bind outer leaflet phosphatidylserine on apoptotic and necrotic cells 45 . The complement component C1q promotes phagocytosis of dying cells by macrophages [46] [47] [48] . We measured higher levels of the C1q genes C1qa, C1qb, and C1qc in F4/80 HI macrophages from fetal lung compared to CD11b HI macrophages. These data suggest that yolk sac derived F4/80 HI macrophages play important roles in removing apoptotic or necrotic cells during tissue morphogenesis. F4/80 HI macrophages also expressed IGF-1, a major promoter of both developmental morphogenesis and tissue repair and regeneration. Macrophage IGF-1 contributes to muscle repair following injury 49 . In the lung, macrophage phagocytosis of apoptotic cells in the lung releases IGF-1, which then stimulates additional phagocytic function in adjacent airway epithelial cells 50 . The transcription factors MafB and C/EBPγ were both detected in Nanostring analysis of F4/80 HI macrophages, and both factors drive anti-inflammatory cell phenotypes 51, 52 . Data therefore suggest that anti-inflammatory fetal F4/80 HI macrophages could be tasked with removing damaged cells and cellular debris during morphogenesis while pro-inflammatory CD11b
HI macrophages respond to microbial products and innate immune activators. The unique functions of fetal macrophage populations could impact disease processes. Early in development, the lack of proinflammatory macrophages prevents a robust innate immune response. Upon appearance of activation competent CD11b HI macrophages in various tissues, TLR activation can lead to regional or systemic inflammation in the developing fetus. Future experiments will need to implement novel approaches for depleting specific fetal macrophage populations, as our antibody-based strategy was inefficient at cell depletion. Intrauterine fetal inflammation plays a major role in causing preterm birth and the long-term sequelae of extreme prematurity 53 . Inflammatory processes and tissue injury are associated with necrotizing enterocolitis 54 , bronchopulmonary dysplasia 55 , and retinopathy of prematurity 56 . If our data in mice translate to the development of human innate immunity, interventions targeting macrophage activation and inflammation processes will need to focus on specific pro-inflammatory macrophage populations.
